stockrowExelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) Total debt
Exelixis, Inc.'s total debt at the end of fiscal 2022 was $190.0M, up 272.5% from $51.0M in fiscal 2021. At the end of the quarter to 30 September 2023 it was $191.0M. Over the past ten years it has ranged from $12.0M (fiscal 2018) to $417.9M (fiscal 2015); the current reading is higher than 88% of that period. Exelixis, Inc. ranks 61st of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2022 | $190.0M | 272.55% |
| FY2021 | $51.0M | 4.08% |
| FY2020 | $49.0M | 2.08% |
| FY2019 | $48.0M | 300.00% |
| FY2018 | $12.0M | (19.67%) |
| FY2017 | $14.9M | (92.10%) |
| FY2016 | $189.0M | (54.78%) |
| FY2015 | $417.9M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Sep 2023 | $191.0M | (2.05%) |
| Jun 2023 | $195.0M | 4.28% |
| Mar 2023 | $187.0M | (1.58%) |
| Dec 2022 | $190.0M | 18.75% |
| 25 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $5.6B |
| HALO Halozyme Therapeutics, Inc. compare | $3.3B |
| BBIO BridgeBio Pharma, Inc. compare | $1.9B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.0B |
| INSM Insmed, Inc. compare | $562.8M |
| ASND Ascendis Pharma A/S compare | $523.3M |
| BNTX BioNTech SE Sponsored ADR compare | $414.1M |
| EXEL Exelixis, Inc. | $191.0M |
| SMMT Summit Therapeutics PLC compare | $100.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on EXEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement